Clinical Trial Update: Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing carboplatin versus docetaxel in women with metastatic BRCA1/BRCA2-mutated breast cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hereditary Breast and Ovarian Cancer Syndrome

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University College London Hospitals | Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier | Phase 2 | Status: COMPLETED